Razoxane

Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer[1][2].

Product Specifications

CAS Number

[21416-67-1]

Product Name Alternative

ICRF 159

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/razoxane.html

Concentration

10mM

Purity

99.16

Solubility

10 mM in DMSO

Smiles

CC(CN(CC(N1)=O)CC1=O)N(CC(N2)=O)CC2=O

Molecular Formula

C11H16N4O4

Molecular Weight

268.27

Precautions

H315, H319, H335

References & Citations

[1]J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6 (12) :4697-704.|[2]F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5 (1) :9-16.